Datasets that support the main figures published in Sneyers et al, Cell Death and Disease (2023). The project aims to decipher how BAPTAi limits the survival of B-cell cancers, more specifically by its Ca2+-independent effects. We can conclude from these data that BAPTAi inhibits the activity of the glycolytic enzyme PFKFB3, thereby deactivating mTORC1-driven translation, resulting in MCL-1 downregulation. As a consequence, BAPTAi treatment results in cell death in MCL-1 dependent cancers.